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Nivolumab is an immune checkpoint inhibitor that binds to the
Programmed death 1 (PD-1) receptor and blocks its interaction
withPD-L1andPD-L2, thereby reversing tumor-inducedsuppression
of tumor-speciﬁc T cells.1,2 Nivolumab is currently approved for the
treatment of metastatic melanoma, squamous cell lung cancer, and
renal cell cancer. Although generally well tolerated, nivolumab can
induce immune-related pneumonitis. We herein describe a case of
severe pneumonitis after nivolumab treatment for melanoma.
A 73-year-old woman with metastatic melanoma (brain, lung)
presented to our institution with fever, fatigue, and non-productive
cough. Five months prior to presentation, she had begun treatment
withnivolumab(2mg/kg, every threeweeks).After sixcyclesof treat-
ment, one week prior to presentation, she developed fever, fatigue,
and non-productive cough. Her past medical history was signiﬁcant
for thoracic aortic aneurysm status post stent graft. She was a non-
smoker and had no history of chronic lung disease. On examination,
body temperature was 37.0 C, blood pressure was 121/75 mm Hg,
heart rate was 82/min, and oxygen saturation on room air was 95%.
Her physical examination was unremarkable. Laboratory tests
demonstratedwhite blood cell count of 10,970/mLwith 85.6% neutro-
phils and 6.1% lymphocytes, C-reactive protein level of 14.3 mg/dL
(normal <0.3 mg/dL), serum lactate dehydrogenase (LDH) level of
138 IU/L (normal, 119e229 IU/L), and Krebs von den Lungen-6 (KL-
6) level of 250 U/mL (normal <500 U/mL). Arterial blood gas analysis
on room air showed pH of 7.479, PaCO2 of 37.6 mmHg and PaO2 of
61.0 mmHg. Chest radiography showed a right lung inﬁltrate and
blunting of the right costophrenic angle. Chest computed tomogra-
phy (CT) scan revealed a consolidation with air bronchograms,
ground-glass attenuations, and patchy shadows, predominantly in
the right lung. These abnormalities mainly involved the dependent
lung regions. A right pleural effusion was also present. A metastatic
lung tumor was found in the left lower lobe, but no abnormalities
were observed around the tumor (Fig. 1). Although sputum culture
didnot reveal anymicroorganisms, includingmycobacteria and fungi,
she was initially diagnosed with bacterial pneumonia due to her
symptoms and CT ﬁndings. Nivolumab was discontinued, and tazo-
bactam/piperacillin (TAZ/PIPC) and levoﬂoxacin (LVFX) antibiotics
were initiated, but her symptoms did not improve. On hospital day
11, TAZ/PIPC was switched to meropenem (MEPM). However, she
developed progressive dyspnea with severe hypoxemia, and the
diffuse consolidation, ground-glass attenuations, and pleural effu-
sions worsened on CT imaging, in a pattern suggestive of diffusePeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).alveolar damage. Onhospital day 16, shewas transferred to the inten-
sive care unit and started onmechanical ventilation. The serum level
of surfactant protein-D was increased to 213.7 ng/mL (normal
<110 ng/mL), but LDH (243 IU/L) and KL-6 (327 U/mL) were within
normal limits. Bronchoalveolar lavage (BAL) showed a total cell count
of 3.1105 cells/mLwith 77.7%macrophages, 8.7% lymphocytes, and
14.3% neutrophils, with no evidence of bacteria, fungi or malignancy.
The pleural ﬂuidwas also sterile. An echocardiogramdid not demon-
strate any underlying cardiac dysfunction. Her PaO2/FIO2 ratio was
131, and shewas ultimately diagnosedwith acute respiratory distress
syndrome secondary to nivolumab treatment (Grade 4). Intravenous
methylprednisolone (mPSL) pulse therapy (1 g per day for threedays)
and continuous infusion of sivelestat sodium hydrate were initiated.
Her respiratory failure continued toworsen, prompting the adminis-
trationof500mgof intravenouscyclophosphamide (IVCY)andrepeat
mPSL pulse therapy. Shortly thereafter, her respiratory status and
radiographic ﬁndings began to improve. Following the mPSL pulses,
oral prednisolone (PSL) at a dose of 2 mg/kg/day was administered
and gradually tapered (Fig. 2). The patient was discharged from the
intensive careunit35days afterpresentation, liberated frommechan-
icalventilationafter65days, andwasdischarged fromourhospital af-
ter 120days.Oneyear following the last administration of nivolumab,
pneumonitishadnot returnedand themetastatic lungtumorwassta-
ble on chest CT imaging.
In a phase I study of nivolumab, 3% of patients (9 of 269) expe-
rienced drug-related pneumonitis, and 1% (3 of 269) developed
grade 3e4 pneumonitis.3 Long-term safety outcomes from another
phase I study revealed similar results.4 Three treatment-related
deaths occurred as a result of pneumonitis; 2 of these patients
were being treated for non-small cell lung cancer and 1 was being
treated for colorectal cancer.3,4 Currently, management guidelines
for immune-mediated adverse reactions include discontinuation
of nivolumab, with the addition of corticosteroids and immunosup-
pressants (inﬂiximab, cyclophosphamide, intravenous immune
globulin, or mycophenolate mofetil) in grade 3 or 4 pneumonitis.5
We used cyclophosphamide for our patient because we had very
little experience with other immunosuppressants.
Very few cases of nivolumab-induced pneumonitis have been
reported in detail. Nishino et al. recently reported the development
of pneumonitis in 3 patients with melanoma who had received
either nivolumab alone or nivolumab and ipilimumab sequen-
tially.6 In each case (one case of grade 2 and two cases of grade 3
pneumonitis), ﬁndings were associated with anti-PD-1 antibodies.
All cases had evidence of ground glass, reticulations and consolida-
tions on chest CT imaging, and one case developed a pleural effu-
sion. Discontinuation of nivolumab and initiation of oralvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Chest computed tomography showing consolidation with air bronchograms, ground-glass attenuations, and patchy shadows, predominantly in the right lung. A right pleural
effusion is also present. No abnormalities were observed around the metastatic tumor in the lung.
Fig. 2. Clinical course. Abbreviations: mPSL, methylprednisolone pulse therapy; IVCY, intermittent pulse intravenous cyclophosphamide therapy; PSL, prednisolone; LVFX, levoﬂox-
acin; TAZ/PIPC, tazobactam/piperacillin; MEPM, meropenem.
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ever the grade 3 cases required additional treatment with inﬂixi-
mab. With this additional treatment, one case resolved after 10
weeks and one case ended in the patient's death 4weeks after diag-
nosis. Nivolumab has also been associated with the development of
organizing pneumonia in a patient with metastatic melanoma; the
patient improved with corticosteroid therapy.7,8 Thus, nivolumab
may cause several types of adverse lung reactions, each with
different severity and treatment response.
Identifying drug-induced pneumonitis can be difﬁcult. For
example, our patient was initially treated for bacterial infection
based on CT ﬁndings of asymmetrical consolidation with air bron-
chograms and pleural effusion. However, given the lack of improve-
ment with antibiotics, as well as negative sputum, BAL and pleural
ﬂuid cultures, she was ultimately diagnosed with nivolumab-
associated pneumonitis. Though she improved with discontinua-
tion of nivolumab and initiation of corticosteroids and cyclophos-
phamide, the delay in diagnosis may have contributed to her
prolonged clinical course. Another challenging point is differenti-
ating between immune-related adverse events and immune-
reactions against tumor cells. In clinical trials of PD-1 or PD-L1 an-
tibodies, some patients experienced a transient increase in the size
of tumor lesions. The increase was associated with edema and im-
mune cell inﬁltrates.9 In our case as well as previously reported
cases,7,8 extensive ground-glass opacities and consolidations were
observed in areas without tumor lesions, but similar ﬁndings
were not observed around the metastatic tumors. This observation
might be useful in differentiating these two immune reactions.
As nivolumab is approved for additional therapeutic indications,
the number of patients treated with this drug is expected to in-
crease. Hence, the incidence of nivolumab-induced pneumonitis
may also increase. This adverse event should be suspected in pa-
tients receiving nivolumab who present with acute onset respira-
tory failure or worsening of chronic respiratory symptoms. Given
the high mortality risk of nivolumab-induced pneumonitis, any
suspicion of this etiology of respiratory failure should prompt clin-
ical investigations including cross-sectional imaging and bronchos-
copy, if appropriate, and treatment should include immediate
cessation of nivolumab and addition of corticosteroids and immu-
nosuppressants. Further studies on the prevalence, risk factors,
clinical features, chest CT ﬁndings and treatment outcomes for
nivolumab-induced pneumonitis are warranted.Conﬂict of interest
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